IBC
6.3.2019 10:12:09 CET | Business Wire | Press release
The IBC2019 Awards are now open for entries, with the aim of celebrating excellence across the industry. From the most exciting technical achievements in media, entertainment and technology to outstanding individual accomplishments and projects that have made a positive social impact, the IBC Awards are a coveted mark of recognition from industry peers in keeping with IBC’s ethos of being ‘by the industry, for the industry’.
IBC is pleased to announce two new categories this year, which reflect the way the industry is developing globally. The Young Pioneer Award celebrates the newest, brightest talent in the industry. From the entries, the top thirty rising stars demonstrating outstanding passion, ambition and commitment to their work, whether in a creative, technical, commercial or strategic role, will be shortlisted in the ‘IBC365 30 under 30 list’ with the stand-out entry winning the Young Pioneer Award. The Social Impact Award will recognise a company initiative or campaign that is making a positive impact in the wider world, tackling an issue that is important within the context of the industry such as sustainability, diversity or health. Both of these new award categories are free to enter.
“It's important for IBC to shine a light on rising talent and to recognise achievements that push the industry to ever greater heights. We are excited to introduce these new awards to celebrate how talented professionals in our sector are accomplishing great things” said Jaisica Lapsiwala, Head of Content, IBC.
Returning for 2019 are the much sought-after Innovation Awards, championing the creativity of projects and the teams behind them. As the disruption of the media, entertainment and technology industry continues and the convergence with other verticals accelerates, the judges are keen to see examples of productive collaboration that leads to innovative solutions for the challenges and opportunities created. The size and scale of a project is unimportant as long as the entry demonstrates ground-breaking innovation and solves a real-world problem in a creative way. The three Innovation Award categories are Content Creation, Content Distribution and Content Everywhere .
Entries will benefit from the dedicated global marketing programme surrounding the awards and are invited to attend the awards ceremony, which takes place during IBC on Sunday 15 September in the RAI Auditorium, Amsterdam. The ceremony will also see several Outstanding Achievement Awards bestowed by the judges, including IBC’s most prestigious award, the International Honour for Excellence.
The deadline for submissions is Tuesday 23 April 2019.
Full details on how to enter can be found at show.ibc.org/awards .
## ENDS ##
Notes to Editors:
About IBC
IBC is the world’s most influential media, entertainment and technology show, attracting 55,000+ attendees from more than 170 countries and combining a highly respected and peer-reviewed conference with an exhibition that showcases 1,700+ leading industry suppliers of state-of-the-art technology. In addition to the world-class exhibition and conference, IBC also encompasses the IBC Daily, IBCTV and IBC365.
IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.
IBC2019 Dates
Conference: 13 - 17 September 2019
Exhibition: 13 - 17 September 2019
For more information about IBC2019 visit: show.ibc.org/awards .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190306005278/en/
Contact:
Amy Swallow, Bubble Agency E: amys@bubbleagency.com T: +44 7872 831167
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom